Taizhou Huan Sheng Investment Management Company, a subsidiary of 3SBio, will manage 3SBio Ventures. Taizhou Oriental and 3SBio have committed RMB50m and RMB200m respectively to the fund, with 20% of the total drawn down initially.
3SBio, a China-based biotechnology company, has formed an a RMB250m ($40m) corporate venturing fund with Taizhou Oriental, the investment division of Taizhou China Medical City Company (CMC), a high-tech industrial park dedicated to life science innovation supported directly by the country’s ministries.
Taizhou Huan Sheng Investment Management Company, a subsidiary of 3SBio, will manage 3SBio Ventures. Taizhou Oriental and 3SBio have committed RMB50m and RMB200m respectively to the fund, with 20% of the total drawn down initially.
3SBio Ventures…
